Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Innovation Council · Running

bioSWITCH Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics

Coordinator
Linkopings Universitet, Sweden
Runs
1 March 2023 to 28 February 2027
Status
Running
EU funding
€4.4m
Total cost
€4.4m
Partners
7 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101099963

What the project is doing

In the project's own words, from its summary on CORDIS.

Our vision for a new type of cancer treatment is based on an implantable therapeutic system capable of ‘programmable’ on-demand delivery of drugs directly to the tumor. We conceive an implantable iontronic switch (bioSWITCH) to enable a spatiotemporally controlled administration of highly potent chemotherapeutics, without the need for systemic administration of (pro)drugs or drug conjugates. This radically new technology will be realized by a combination of next-level tools.

As a result, bioSWITCH can generate previously unobtainable discrete as well as continuous drug concentration profiles at the tumor site, and thus allows for the use of highly potent drugs that are otherwise not applicable due to high cytotoxicity. The goal is to demonstrate the technology’s potential to effectively interfere with tumor progression using a xenograft pancreas cancer mouse model. Efficiently shrinking tumors in size allows for surgical resection of previously non-operable tumors and dramatically increases survival rates.

Our consortium of world leading academics and pioneering SMEs will ensure the translation of this disruptive technology into the market to maximize the socioeconomic impact.

Topics

Who is involved

OrganisationCityCountryRole
Linkopings UniversitetLinkopingSwedenCoordinator
Medizinische Universitat GrazGrazAustriaParticipant
Technische Universitaet WienWienAustriaParticipant
Hun-Ren Termeszettudomanyi KutatokozpontBudapestHungaryParticipant
Suprapolix BVEindhovenNetherlandsParticipant
Tagworks Pharmaceuticals BVNijmegenNetherlandsParticipant
Oboe Ipr ABLinkopingSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI